Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 38 12 76 29 6 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:987
ICD10 33 L65.9
ICD9CM 35 704.0 704.00
MeSH 44 D000505
NCIt 50 C50575
SNOMED-CT 68 56317004
UMLS 73 C0002170

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and clouston syndrome, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is HR (HR, Lysine Demethylase And Nuclear Receptor Corepressor), and among its related pathways/superpathways are Adhesion and Cell adhesion_Endothelial cell contacts by junctional mechanisms. The drugs Clobetasol and Acitretin have been mentioned in the context of this disorder. Affiliated tissues include Hair and Hair, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 595)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 34.0 AIRE FOXN1 HR MBTPS2
2 clouston syndrome 32.2 ANTXR1 GJA1 TP63
3 nail disorder, nonsyndromic congenital, 1 31.8 AIRE MBTPS2 TP63
4 hypotrichosis 31.7 DCAF17 GJA1 HR KRT86
5 keratosis 30.1 DSP GJA1 MBTPS2
6 hypohidrosis 29.9 KRT14 TP63
7 alopecia areata 12.7
8 alopecia, androgenetic, 1 12.5
9 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 12.5
10 alopecia totalis 12.4
11 frontal fibrosing alopecia 12.4
12 mandibulofacial dysostosis with alopecia 12.4
13 palmoplantar keratoderma and congenital alopecia 2 12.3
14 central centrifugal cicatricial alopecia 12.3
15 androgenic alopecia 12.3
16 polyposis, skin pigmentation, alopecia, and fingernail changes 12.3
17 alopecia, epilepsy, pyorrhea, mental subnormality 12.3
18 diffuse alopecia areata 12.3
19 autosomal dominant palmoplantar keratoderma and congenital alopecia 12.3
20 palmoplantar keratoderma and congenital alopecia 1 12.3
21 alopecia, neurologic defects, and endocrinopathy syndrome 12.3
22 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.3
23 alopecia-contractures-dwarfism-intellectual disability syndrome 12.3
24 alopecia-contractures-dwarfism mental retardation syndrome 12.3
25 alopecia-mental retardation syndrome 1 12.2
26 autosomal recessive palmoplantar keratoderma and congenital alopecia 12.2
27 alopecia-intellectual disability syndrome 12.2
28 alopecia, congenital 12.2
29 odonto onycho dysplasia with alopecia 12.1
30 alopecia areata 1 12.1
31 ichthyosis alopecia eclabion ectropion mental retardation 12.1
32 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 12.1
33 alopecia-mental retardation syndrome 2 12.1
34 alopecia-mental retardation syndrome 3 12.1
35 alopecia universalis onychodystrophy vitiligo 12.1
36 alopecia-epilepsy-oligophrenia syndrome of moynahan 12.0
37 woodhouse-sakati syndrome 12.0
38 alopecia universalis congenita, xy gonadal dysgenesis, and laryngomalacia 12.0
39 growth retardation alopecia pseudoanodontia optic 12.0
40 gapo syndrome 12.0
41 lichen planopilaris 12.0
42 frontonasal dysplasia with alopecia and genital anomaly 12.0
43 thumb deformity and alopecia 11.9
44 hypergonadotropic hypogonadism and partial alopecia 11.9
45 alopecia, androgenetic, 2 11.9
46 alopecia areata 2 11.9
47 alopecia, androgenetic, 3 11.9
48 alopecia intellectual disability syndrome 2 11.9
49 alopecia, familial focal 11.9
50 ichthyosis with alopecia, eclabium, ectropion, and mental retardation 11.9

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus, exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10.2 GJA1
2 Decreased viability GR00381-A-1 10.2 KRT86
3 Decreased viability GR00402-S-2 10.2 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
4 Mildly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.77 AHSG AIRE ANTXR1 AR DCAF17 DSP
5 no effect GR00402-S-1 9.62 AHSG AIRE ANTXR1 AR AUTS2 CLDN1

MGI Mouse Phenotypes related to Alopecia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.35 AHSG AIRE ANTXR1 AR AUTS2 CLDN1
2 cellular MP:0005384 10.33 ANTXR1 AR AUTS2 DCAF17 DSP EDNRA
3 cardiovascular system MP:0005385 10.3 ANTXR1 AR AUTS2 DSP EDNRA FOXN1
4 endocrine/exocrine gland MP:0005379 10.24 AIRE ANTXR1 AR AUTS2 EDNRA FOXN1
5 craniofacial MP:0005382 10.19 ANTXR1 AR DSP EDNRA GJA1 HR
6 mortality/aging MP:0010768 10.18 AIRE ANTXR1 AR AUTS2 CLDN1 DSP
7 digestive/alimentary MP:0005381 10.13 AIRE AR DSP EDNRA HR KRT14
8 immune system MP:0005387 10.13 AIRE ANTXR1 AR EDNRA FOXN1 GJA1
9 embryo MP:0005380 10.11 AR AUTS2 DSP EDNRA FOXN1 GJA1
10 integument MP:0010771 10.1 AR CLDN1 DSP EDNRA FOXN1 GJA1
11 hearing/vestibular/ear MP:0005377 10 AHSG EDNRA FOXN1 GJA1 HR KRT14
12 muscle MP:0005369 9.92 AHSG AR DSP EDNRA FOXN1 GJA1
13 neoplasm MP:0002006 9.86 AIRE ANTXR1 AR AUTS2 FOXN1 HR
14 reproductive system MP:0005389 9.85 AIRE ANTXR1 AR DCAF17 FOXN1 GJA1
15 skeleton MP:0005390 9.61 AHSG ANTXR1 AR EDNRA FOXN1 GJA1
16 vision/eye MP:0005391 9.23 AIRE EDNRA FOXN1 GJA1 HR HTRA1

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 497)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3 25122-46-7, 25122-41-2 5311051 32798
2
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
3
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 38304-91-5 4201
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
9 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3 979-32-8
10
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Polyestradiol phosphate Approved Phase 4,Phase 3 28014-46-2
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
14
Abatacept Approved Phase 4,Phase 2 332348-12-6 10237
15
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
16
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
17
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5311221 5282380
18
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
19
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 99011-02-6 57469
20
Hydroxychloroquine Approved Phase 4 118-42-3 3652
21 Orange Approved Phase 4,Phase 1,Not Applicable
22
Capsaicin Approved Phase 4,Not Applicable 404-86-4 1548943
23
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
24
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
25
Drospirenone Approved Phase 4 67392-87-4 68873
26
Aminolevulinic acid Approved Phase 4,Phase 3,Not Applicable 106-60-5 137
27
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 445643 439492
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
29
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 94-09-7, 1994-09-7 2337
31 tannic acid Approved Phase 4,Phase 3,Phase 2
32
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
33
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
34
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
35
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
36
Ketoconazole Approved, Investigational Phase 4 65277-42-1 3823 47576
37
Levonorgestrel Approved, Investigational Phase 4,Phase 3 17489-40-6, 797-63-7 13109
38
Desogestrel Approved Phase 4 54024-22-5 40973
39
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
40
Spironolactone Approved Phase 4,Phase 2 52-01-7, 1952-01-7 5833
41
Apremilast Approved, Investigational Phase 4,Phase 2,Not Applicable 608141-41-9 11561674
42
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
43
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
45
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
46
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
47
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Not Applicable 2920-86-7
48
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 31703
49
Cobalamin Experimental Phase 4 13408-78-1 6438156
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 655)
# Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
2 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
3 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
4 Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
5 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
6 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
7 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
8 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
9 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
10 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
11 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
12 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
13 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
14 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
16 The Vienna Prograf and Endothelial Progenitor Cell Study Completed NCT00182559 Phase 4 Ciclosporin;Tacrolimus
17 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
18 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
19 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
20 Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Recruiting NCT03422640 Phase 4 Apremilast
21 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
22 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
23 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
24 Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
25 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
26 Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant Active, not recruiting NCT03353012 Phase 4 Etonogestrel Drug Implant;Levonorgestrel Drug Implant
27 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
28 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
29 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
30 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Not yet recruiting NCT03800979 Phase 4 Tofacitinib
31 Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Not yet recruiting NCT03473600 Phase 4 Triamcinolone acetonide injection
32 Pain Outcomes Following Intralesional Corticosteroid Injections Not yet recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
33 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
34 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
35 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
36 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
37 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
38 Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation Unknown status NCT01615757 Phase 3 Ara-c;Ara-c
39 Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Unknown status NCT01671384 Phase 3 Valproate, Levocarnitine;Placebo
40 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
41 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
42 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
43 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
44 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
45 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
46 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
47 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
48 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
49 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
50 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 29

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

41
Breast, Skin, Ovary, T Cells, Prostate, Brain, Thyroid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 3263)
# Title Authors Year
1
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
2
Alopecia areata. ( 29908825 )
2018
3
Reply to: "Updated diagnostic criteria for frontal fibrosing alopecia". ( 29241803 )
2018
4
Frontal Fibrosing Alopecia and Concomitant Lichen Planus Pigmentosus: A Case Series of Seven African American Women. ( 29601616 )
2018
5
Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )
2018
6
Chronological clinicopathological characterization of rapidly progressive alopecia areata resistant to multiple i.v. corticosteroid pulse therapies: An implication for improving the efficacy. ( 29963718 )
2018
7
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female. ( 29409504 )
2018
8
Alopecia Areata-like Hair Loss Accompanying Toxic Epidermal Necrolysis. ( 29856464 )
2018
9
Coexistence of Dermatomyositis and Alopecia Areata: Insight into Pathogenesis. ( 29854645 )
2018
10
An investigation of vitamin D status in alopecia areata. ( 29869122 )
2018
11
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis. ( 29452121 )
2018
12
Fibroblast cell-based therapy prevents induction of alopecia areata in an experimental model. ( 29871523 )
2018
13
Histopathology of facial papules in frontal fibrosing alopecia and therapeutic response to oral isotretinoin. ( 29332726 )
2018
14
Ultraviolet filters in hair-care products: a possible link with frontal fibrosing alopecia and lichen planopilaris. ( 28994172 )
2018
15
Frontal fibrosing alopecia and cutaneous comorbidities: A potential relationship with rosacea. ( 29447678 )
2018
16
5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update. ( 29524253 )
2018
17
Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases. ( 29241787 )
2018
18
IgG4-related disease presenting with scarring alopecia of the scalp. ( 29892674 )
2018
19
Detection of titanium nanoparticles in the hair shafts of a patient with frontal fibrosing alopecia. ( 29578625 )
2018
20
Vitamin D-Dependent Rickets Type II with Alopecia: A Rare Case Report. ( 29692463 )
2018
21
Acknowledging the pseudo "fringe sign" in frontal fibrosing alopecia has diagnostic and prognostic implications. ( 29241801 )
2018
22
Annular Alopecia Areata: A Morphologically Rare Variant. ( 29440858 )
2018
23
Buschke-Ollendorff syndrome due to a novel LEMD3 mutation - an unusual case of alopecia. ( 29465813 )
2018
24
Quality of life in mild and severe alopecia areata patients. ( 29872683 )
2018
25
Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. ( 29656764 )
2018
26
The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: a Korean population-based retrospective cohort study. ( 29955877 )
2018
27
Alopecia Areata: The Clinical Situation. ( 29273111 )
2018
28
Case Report of Connubial Frontal Fibrosing Alopecia. ( 29769781 )
2018
29
Spontaneous hair regrowth in eight patients with severe alopecia areata. ( 29931820 )
2018
30
Clinical Description of Frontal Fibrosing Alopecia with Concomitant Lichen Planopilaris. ( 29765970 )
2018
31
Sarcoidosis Presenting as Frontal Fibrosing Alopecia: A Master Mimicker or a Coincidental Finding? ( 29293480 )
2018
32
Platelet-Rich Plasma for the Treatment of Androgenic Alopecia: A Systematic Review. ( 29954021 )
2018
33
Big Data Reveal Insights into Alopecia Areata Comorbidities. ( 29273109 )
2018
34
Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata. ( 29951053 )
2018
35
Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient. ( 29377270 )
2018
36
Persistent neutrophilic scarring alopecia triggered by anti-TNF blockade for Crohn's disease. ( 29976546 )
2018
37
Association of Uterine Leiomyomas With Central Centrifugal Cicatricial Alopecia. ( 29282458 )
2018
38
'Corkscrews' on the patchy alopecia of a girl. ( 29950301 )
2018
39
Retrospective review of 18 British South Asian women with frontal fibrosing alopecia. ( 29384198 )
2018
40
Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. ( 29981403 )
2018
41
Fibroproliferative Genes are Preferentially Expressed in Central Centrifugal Cicatricial Alopecia. ( 29913259 )
2018
42
Hemorrhagic Ischemic Retinal Vasculitis and Alopecia Areata as a Manifestation of HLA-B27. ( 29304269 )
2018
43
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia. ( 29443105 )
2018
44
Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. ( 29101437 )
2018
45
A novel PLEC nonsense homozygous mutation (c.7159Ga88>a88T; p.Glu2387*) causes epidermolysis bullosa simplex with muscular dystrophy and diffuse alopecia: a case report. ( 29352809 )
2018
46
Facial Papules in Frontal Fibrosing Alopecia: Good Response to Isotretinoin. ( 29395031 )
2018
47
Updated diagnostic criteria for frontal fibrosing alopecia. ( 29241802 )
2018
48
Applying the Common Sense Model to predicting quality of life in alopecia areata: The role of illness perceptions and coping strategies. ( 29355049 )
2018
49
Photopatch and patch testing in 63 frontal fibrosing alopecia patients: a case series. ( 29962055 )
2018
50
Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO). ( 29874239 )
2018

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SASH1 NM_015278.4(SASH1): c.1849G> A (p.Glu617Lys) single nucleotide variant Likely pathogenic rs587781245 GRCh38 Chromosome 6, 148533885: 148533885
2 SASH1 NM_015278.4(SASH1): c.1849G> A (p.Glu617Lys) single nucleotide variant Likely pathogenic rs587781245 GRCh37 Chromosome 6, 148855021: 148855021
3 EMILIN2; LPIN2; METTL4; MYL12A; MYL12B; MYOM1; NDC80; SMCHD1; TGIF1 GRCh37/hg19 18p11.32-11.31(chr18: 1345040-3479168) copy number loss Uncertain significance GRCh37 Chromosome 18, 1345040: 3479168

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

Pathways related to Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 CLDN1 DSP GJA1
2 10.3 CLDN1 DSP GJA1

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.96 DSP GJA1
2 intermediate filament GO:0005882 8.92 DSP GJA1 KRT14 KRT86

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 AIRE AR AUTS2 FOXN1 TP63 VDR
2 cell proliferation GO:0008283 9.81 AR EDNRA FOXN1 TP63
3 skeletal system development GO:0001501 9.7 AHSG TP63 VDR
4 animal organ morphogenesis GO:0009887 9.54 FOXN1 TP63 VDR
5 cornification GO:0070268 9.5 DSP KRT14 KRT86
6 cell-cell junction organization GO:0045216 9.48 CLDN1 GJA1
7 decidualization GO:0046697 9.46 GJA1 VDR
8 regulation of bone mineralization GO:0030500 9.43 AHSG GJA1
9 establishment of skin barrier GO:0061436 9.4 CLDN1 TP63
10 keratinocyte differentiation GO:0030216 9.33 DSP FOXN1 TP63
11 prostate gland development GO:0030850 9.26 AR TP63
12 epidermis development GO:0008544 9.26 DSP FOXN1 KRT14 TP63
13 thymus epithelium morphogenesis GO:0097536 8.62 AIRE FOXN1

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....